Sort   by:  
 Page size 
UnknownCombining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections.
Not available
S-EPMC8669489 | biostudies-literature
UnknownClinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study.
Not available
S-EPMC7713571 | biostudies-literature
UnknownIncreased complement activation is a distinctive feature of severe SARS-CoV-2 infection.
Not available
S-EPMC7924264 | biostudies-literature
UnknownPhase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection.
Not available
S-EPMC3756431 | biostudies-literature
UnknownThe future of cystic fibrosis care: a global perspective.
Not available
S-EPMC8862661 | biostudies-literature
UnknownTocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8084355 | biostudies-literature
UnknownBaricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
Not available
S-EPMC9333998 | biostudies-literature
UnknownA Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment.
Not available
S-EPMC8786075 | biostudies-literature
UnknownLipid phenotyping of lung epithelial lining fluid in healthy human volunteers.
Not available
S-EPMC6153688 | biostudies-literature
UnknownFactors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study.
Not available
S-EPMC9189103 | biostudies-literature
Sort   by:  
 Page size